Estée Lauder's stock falls on weak outlook due to China declines
By Steve Gelsi
Beauty company's projected 2025 adjusted earnings misses analyst estimates
Estée Lauder Cos. stock was down 1.6% in morning trades Monday after the cosmetics company's outlook for fiscal 2025 came in below analyst estimates due partly to "persistent weak sentiment among Chinese consumers."
Estée Lauder (EL) said its fourth-quarter loss widened to $284 million, or 79 cents a share, from a loss of $33 million, or 9 cents a share, in the year-ago period.
Adjusted fourth-quarter earnings of 64 cents a share beat the FactSet consensus estimate of 26 cents a share.
Revenue rose 7% to $3.87 billion, ahead of the analyst projection of $3.81 billion.
For fiscal 2025, Estée Lauder said it expects adjusted earnings of $2.75 a share to $2.95 a share, below the analyst estimate of $3.97 a share.
Estee Lauder's stock fell $1.52 to $93.45.
L'Oreal's (FR:OR) stock price in Paris slumped after the warning from Estee Lauder.
Separately, it was revealed that Chief Executive Fabrizio Freda plans to retire from the Estée Lauder helm at the end of fiscal year 2025 after 16 years in the job.
Prior to Monday trading, Estée Lauder's stock was down more than 35% in 2024, compared with a 16.5% run-up by the S&P 500 SPX.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-19-24 0952ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks